Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

By J. Heier, David M. Brown, V. Chong, J. Korobelnik, P. Kaiser, Q. Nguyen, B. Kirchhof, A. Ho, Y. Ogura, G. Yancopoulos and 10 more. Ophthalmology (Rochester, Minn.), 2012

2,368 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/0a19c04d4c1007e4ce375fa2e30c9130166d3bc2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Adamis
2. N. Ferrara

In Ophthalmology

1. N. Ferrara
2. A. Adamis

In Radiology, Nuclear Medicine and Imaging

1. N. Ferrara
2. A. Adamis

Citations in the corpus

• Ten years of anti-vascular endothelial growth factor therapy (2016, positive): “…immunoglobulin G (IgG) Fc fusion protein, combining Ig-like domain 2 of VEGF receptor 1 (VEGFR1) and domain 3 of VEGFR2 ) given every other month after three monthly loading doses achieved gains in visual acuity that were comparable to those following monthly 0.5 mg doses of ranibizumab 231 .”